Key Insights

Highlights

Treatment Research

2 treatments under study, led by Ezabenlimab Bi907828

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06084689Phase 2Withdrawn

Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

Showing all 1 trials

Research Network

Common Treatments

  • Ezabenlimab Bi9078281
  • Ezabenlimab1

Active Sponsors

  • Institut Bergonié1
  • Institut Bergonie1
  • Boehringer Ingelheim1

Top Investigators

Related Conditions

  • Triple Negative Breast Cancer1
  • Adult Soft Tissue Sarcoma1
  • Biliary Tract Cancer1
  • Colorectal Cancer1
  • Non Small Cell Lung Cancer1

Activity Timeline